Back to top
more

Mirati Therapeutics, Inc. (MRTX)

(Delayed Data from NSDQ)

$63.93 USD

63.93
353,481

+2.52 (4.10%)

Updated May 3, 2019 04:00 PM ET

After-Market: $64.05 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

BioMarin Pharmaceutical (BMRN) Surpasses Q3 Earnings Estimates

by Zacks Equity Research

BioMarin (BMRN) delivered earnings and revenue surprises of 21.62% and 1.53%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Mirati (MRTX) Up 5.3% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Amgen's (AMGN) Lumakras Meets Goal in New Lung Cancer Study

by Zacks Equity Research

Amgen's (AMGN) phase III CodeBreaK 200 study evaluating once-daily oral, Lumakras, for treating KRAS G12C-mutated non-small cell lung cancer meets its primary endpoint.

Mirati (MRTX) Q2 Loss Narrower Than Expected, Sales Beat

by Zacks Equity Research

Mirati Therapeutics' (MRTX) Q2 earnings and sales beat the mark. The company plans to start early-stage clinical studies for a SOS1 inhibitor by year-end.

Mirati (MRTX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Mirati (MRTX) delivered earnings and revenue surprises of 9.92% and 143.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Sweta Killa headshot

Biotech ETF Tops in June: 5 Stocks That Outperform

by Sweta Killa

Virtus LifeSci Biotech Clinical Trials ETF (BBC) topped the list of the best-performing U.S. equity ETFs in June, gaining about 10%. The rally was driven by traders' "short squeeze" and investors' bargain hunting.

The Zacks Analyst Blog Highlights Bristol Myers, Turning Point Therapeutics, Regeneron, Novavax, and Mirati Therapeutics

by Zacks Equity Research

Bristol Myers, Turning Point Therapeutics, Regeneron, Novavax, and Mirati Therapeutics are part of Zacks top Analyst Blog.

Biotech Stock Roundup: BMY's Acquisition, REGN to Buy Libtayo & More

by Zacks Equity Research

Acquisition and other updates from Bristol Myers (BMY) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.

Mirati (MRTX) Up on Positive Data From NSCLC Study on Adagrasib

by Zacks Equity Research

Mirati (MRTX) gains on positive results from an early stage KRYSTAL-1 study on experimental candidate adagrasib for lung cancer.

Mirati (MRTX) Down 35.5% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Mirati (MRTX) Down 23% on Mixed Data From Lung Cancer Study

by Zacks Equity Research

Mirati (MRTX) posts positive data from a phase II study evaluating its lung cancer candidate adagrasib. However, the drug caused side-effects in a large number of study participants.

Mirati (MRTX) Seeks EU Nod for Adagrasib to Treat Lung Cancer

by Zacks Equity Research

Mirati (MRTX) seeks a nod for its lung cancer candidate adagrasib in the European Union. A regulatory filing in the United States is currently under the FDA review with decision pending this year-end.

Mirati (MRTX) Q1 Loss Wider Than Expected, Sales Beat

by Zacks Equity Research

Mirati Therapeutics (MRTX) reports wider-than-expected Q1 loss while revenues beat the mark. MRTX plans to enter two new candidates into early-stage clinical studies in second-half 2022.

Mirati (MRTX) Down 6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Mirati (MRTX) Focuses on Seeking Nod for KRAS Drug Adagrasib

by Zacks Equity Research

Mirati's (MRTX) regulatory filing to the FDA for adagrasib in second-line NSCLC gets a longer-than-expected review period. MRTX is progressing well with the pipeline development for other candidates.

Mirati (MRTX) Q4 Earnings and Sales Fall Short of Estimates

by Zacks Equity Research

Mirati Therapeutics (MRTX) reports wider-than-expected fourth-quarter loss. Sales miss estimates.

Is a Surprise Coming for Mirati (MRTX) This Earnings Season?

by Zacks Equity Research

Mirati (MRTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Kinjel Shah headshot

5 Drug/Biotech Stocks Set to Outpace Q4 Earnings Estimates

by Kinjel Shah

Let us take a look at some drug/biotech stocks, EVLO, GMDA, APLS, MRTX and ITOS, which are poised to beat on fourth-quarter earnings.

Mirati (MRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

by Zacks Equity Research

Mirati (MRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Mirati (MRTX) Down on Longer Review Period for Adagrasib NDA

by Zacks Equity Research

The FDA accepts Mirati's (MRTX) NDA for its lung cancer candidate, adagrasib. A decision is expected by Dec 14, 2022.

Gilead Sciences (GILD) Q4 Earnings Miss Estimates

by Zacks Equity Research

Gilead (GILD) delivered earnings and revenue surprises of -54.90% and 9.10%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Amgen's (AMGN) KRAS Inhibitor Gets Nod in Japan for Lung Cancer

by Zacks Equity Research

Amgen's (AMGN) KRAS inhibitor, Lumakras, gets approval in Japan for the treatment of KRAS G12C-mutated positive advanced/recurrent non-small-cell lung cancer.

BridgeBio (BBIO), Amgen Partner in Advanced Solid Tumors Study

by Zacks Equity Research

BridgeBio (BBIO) forges an alliance with Amgen to evaluate their respective cancer drugs for the treatment of advanced solid tumors with KRAS G12C mutations.

Amgen's (AMGN) KRAS Inhibitor Gets Nod for Lung Cancer in EU

by Zacks Equity Research

Amgen's (AMGN) Lumykras is the first targeted therapy approved for patients with KRAS G12C mutation in Europe.

Mirati (MRTX), Verastem to Study Cancer Drugs for NSCLC

by Zacks Equity Research

Mirati Therapeutics (MRTX) partners Verastem Oncology (VSTM) to evaluate adagrasib in combination with VS-6766 in KRASG12C-mutant non-small cell lung cancer.